Eric Schordan

Title: Eric Schordan: Innovator in Renal Cell Carcinoma Treatment

Introduction

Eric Schordan is a notable inventor based in Handschuheim, France. He has made significant contributions to the field of medical research, particularly in the treatment of renal cell carcinoma. His innovative approach focuses on the use of PTHrP antagonists, which has the potential to change the landscape of cancer treatment.

Latest Patents

Eric Schordan holds a patent for the "Use of PTHrP antagonists for treating renal cell carcinoma." This invention concerns the application of a PTHrP antagonist in preparing a pharmaceutical composition aimed at treating renal cell carcinoma (RCC) in mammals, especially in human subjects. The invention is particularly advantageous for inhibiting or reducing tumor growth and metastasis formation in kidney cancer, with specific implications for metastatic developments in the lung and liver. He has 1 patent to his name.

Career Highlights

Throughout his career, Eric has worked with esteemed institutions such as Hôpitaux Universitaires de Strasbourg and the National Institute of Health and Medical Research. His work in these organizations has allowed him to contribute to significant advancements in medical research and treatment methodologies.

Collaborations

Eric Schordan has collaborated with notable professionals in his field, including Herve Lang and Jean-Jacques Helwig. These collaborations have further enriched his research and innovation efforts.

Conclusion

Eric Schordan's work in the field of renal cell carcinoma treatment exemplifies the impact of innovative thinking in medicine. His contributions through patents and collaborations highlight the importance of research in developing effective cancer therapies.